Manufacture of Lentiviral Vectors Using Suspension Packaging and Producer Cell Lines Yields Titres Comparable to Transient Process

XOFLX™ cell lines have high transgene tolerance, produce LVV with demonstrated functionality in primary T cells, and have demonstrated absence of RCL formation.

In addition, XOFLX™ Packaging and Producer cells show robust scalability. In summary, XOFLX™ Lenti platform cell lines produce LV vectors comparable to the industry standard four-plasmid method, and reduce manufacturing costs and process variability, improving patient access to LVV-based cell and gene therapies.